Driving Therapy Adoption with AI-Powered Insights for the mBC Market

The Challenge

In the rapidly evolving metastatic breast cancer (mBC) market, pharmaceutical companies face the challenge of efficiently identifying high-potential patients and optimizing engagement strategies. Traditional, reactive approaches to patient identification and trigger deployment often result in missed opportunities, leading to lower therapy adoption rates. Pharmaceutical companies needed a solution to proactively engage patients and improve therapy adoption while optimizing resources.

ProcDNA's Solution

Proactive Patient Identification

Identifies patients most likely to benefit from specific therapies, enabling timely interventions and improving engagement.

Personalized Insights

Delivers tailored insights to sales representatives, helping them prioritize their efforts and customize engagement strategies based on individual patient needs.

Improved Efficiency

Automates patient identification, freeing up sales representatives' time to focus on high-value interactions with healthcare providers and patients.

Enhanced Decision-Making

Provides actionable insights for optimizing marketing campaigns, resource allocation, and overall strategic decision-making.

Impact

Increased Patient Starts

The solution has driven a significant rise in the number of patients initiating therapy, contributing to revenue growth and improving patient outcomes.

Improved Sales Efficiency

By prioritizing high-potential patients, sales representatives have seen an increase in efficiency, enabling them to allocate their time and resources more effectively.

Data-Driven Decision Making

With actionable insights from the solution, companies have been able to make data-driven decisions, optimizing marketing strategies and resource allocation.

Competitive Advantage

Leveraging AI-powered insights has provided companies with a competitive edge in the market, enhancing their position and accelerating therapy adoption.